Visceral leishmaniasis: elimination with existing interventions
- PMID: 21453873
- DOI: 10.1016/S1473-3099(10)70320-0
Visceral leishmaniasis: elimination with existing interventions
Abstract
The world's burden of infectious diseases can be substantially reduced by more-effective use of existing interventions. Advances in case detection, diagnosis, and treatment strategies have made it possible to consider the elimination of visceral leishmaniasis in the Indian subcontinent. The priority must now be to effectively implement existing interventions at the community level by actively finding cases in endemic villages and treating them with single-dose liposomal amphotericin B at primary-health-care centres. Once the elimination target of one case per 10,000 population has been reached, combination therapies involving miltefosine and paromomycin can be introduced to ensure long-term availability of several drugs for visceral leishmaniasis and to protect against resistance.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.Lancet. 2011 Feb 5;377(9764):477-86. doi: 10.1016/S0140-6736(10)62050-8. Epub 2011 Jan 20. Lancet. 2011. PMID: 21255828 Clinical Trial.
-
Combination therapy for visceral leishmaniasis.Lancet. 2011 Feb 5;377(9764):443-4. doi: 10.1016/S0140-6736(10)62237-4. Epub 2011 Jan 20. Lancet. 2011. PMID: 21255829 No abstract available.
-
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.Infect Dis Poverty. 2018 Aug 13;7(1):80. doi: 10.1186/s40249-018-0461-0. Infect Dis Poverty. 2018. PMID: 30099967 Free PMC article.
-
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?Nat Rev Microbiol. 2007 Nov;5(11):873-82. doi: 10.1038/nrmicro1748. Nat Rev Microbiol. 2007. PMID: 17938629 Review.
-
Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies.Clin Microbiol Infect. 2018 Jun;24(6):591-598. doi: 10.1016/j.cmi.2017.11.008. Epub 2017 Nov 11. Clin Microbiol Infect. 2018. PMID: 29138100 Review.
Cited by
-
Aurantoside L, a New Tetramic Acid Glycoside with Anti-Leishmanial Activity Isolated from the Marine Sponge Siliquariaspongia japonica.Mar Drugs. 2024 Apr 12;22(4):171. doi: 10.3390/md22040171. Mar Drugs. 2024. PMID: 38667788 Free PMC article.
-
Assessment of the impact of implementation research on the Visceral Leishmaniasis (VL) elimination efforts in Nepal.PLoS Negl Trop Dis. 2023 Nov 9;17(11):e0011714. doi: 10.1371/journal.pntd.0011714. eCollection 2023 Nov. PLoS Negl Trop Dis. 2023. PMID: 37943733 Free PMC article. Review.
-
Liposomal drug delivery systems for the treatment of leishmaniasis.Parasitol Res. 2022 Nov;121(11):3073-3082. doi: 10.1007/s00436-022-07659-5. Epub 2022 Sep 16. Parasitol Res. 2022. PMID: 36112211 Review.
-
Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis.Front Med (Lausanne). 2021 Nov 17;8:766400. doi: 10.3389/fmed.2021.766400. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34869476 Free PMC article.
-
Scoping review of Neglected Tropical Disease Interventions and Health Promotion: A framework for successful NTD interventions as evidenced by the literature.PLoS Negl Trop Dis. 2021 Jul 6;15(7):e0009278. doi: 10.1371/journal.pntd.0009278. eCollection 2021 Jul. PLoS Negl Trop Dis. 2021. PMID: 34228729 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
